Five of the most recent developments in anti-cancer therapeutics
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
List view / Grid view
European Pharmaceutical Review investigates five of the latest cancer drug approvals and clinical trial results.
FDA approves Nubeqa (darolutamide) as a new treatment for men with non-metastatic castration-resistant prostate cancer.